1. Home
  2. ENGN vs CODA Comparison

ENGN vs CODA Comparison

Compare ENGN & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

SELL

Current Price

$1.95

Market Cap

117.2M

Sector

N/A

ML Signal

SELL

Logo Coda Octopus Group Inc.

CODA

Coda Octopus Group Inc.

SELL

Current Price

$8.39

Market Cap

94.1M

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
ENGN
CODA
Founded
1999
1994
Country
Canada
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
117.2M
94.1M
IPO Year
2023
2007

Fundamental Metrics

Financial Performance
Metric
ENGN
CODA
Price
$1.95
$8.39
Analyst Decision
Buy
Strong Buy
Analyst Count
9
2
Target Price
$4.29
★ $14.00
AVG Volume (30 Days)
★ 1.5M
80.7K
Earning Date
12-21-2026
09-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 56.85
15.62
EPS
N/A
★ 0.36
Revenue
N/A
★ $20,316,161.00
Revenue This Year
N/A
$9.92
Revenue Next Year
N/A
$17.26
P/E Ratio
★ N/A
$23.94
Revenue Growth
N/A
★ 4.98
52 Week Low
$1.40
$7.80
52 Week High
$12.25
$18.00

Technical Indicators

Market Signals
Indicator
ENGN
CODA
Relative Strength Index (RSI) 55.31 35.79
Support Level $1.61 $7.97
Resistance Level $8.93 $10.66
Average True Range (ATR) 0.18 0.46
MACD 0.07 -0.01
Stochastic Oscillator 47.17 23.30

Price Performance

Historical Comparison
ENGN
CODA

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

About CODA Coda Octopus Group Inc.

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

Share on Social Networks: